Background: According to a recent Portuguese study the prevalence of lifetime consumption
of heroin in the global population (age range: 15-74 years) is 0.5%. Methadone is the …

We investigated prescribing patterns for four opioid use disorder (OUD) medications: 1)
injectable naltrexone, 2) oral naltrexone, 3) sublingual or oralmucosal buprenorphine …

Objetivo: Avaliar a frequência do uso de narguilé na população adulta brasileira de 18 a 59
anos. Métodos: Estudo transversal de base populacional utilizando a Pesquisa Nacional de …

Introduction Buprenorphine/naloxone treatment is a highly effective treatment for opioid use
disorder decreasing illicit opioid use and both all-cause and opioid-involved overdose …

Vinte e sete pacientes do sexo masculino, dependentes de álcool, com elevado padrão de
ingesta alcoólica, participaram de ensaio clínico aberto com cloridrati de naltrexona (50 …

Purpose Following a TV documentary in 2013, there was a tremendous increase in low dose
naltrexone (LDN) use in a wide range of unapproved indications in Norway. We aim to …

Background and objective: Opioid maintenance treatment (OMT) is highly available in
Norway, but only 50% of opioid-dependent individuals are enrolled in such programs. This …

Abstract Background and Aims Patients with opioid use disorder (OUD) must be able to
obtain prescribed buprenorphine/naloxone films (BUP/NX) and naloxone nasal spray (NNS) …

Background Although opioid agonist treatments (OAT) with methadone or buprenorphine
are available to treat opioid use disorders (OUD) in Ukraine, OAT acceptability and …

Background Extended-release injectable naltrexone (XR-naltrexone) is effective for
treatment of patients with opioid use disorder (OUD), but initiation remains a barrier due to …